Technetium-99m market seen reaching $6 billion by 2030

The technetium-99m market is projected to grow from $4.99 billion in 2026 to $6.01 billion by 2030, driven by rising demand for diagnostic imaging, nuclear medicine expansion and broader use in cardiac and oncology scans. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Technetium-99m is a core radiopharmaceutical in diagnostic imaging, so demand tracks broader growth in nuclear medicine and early disease detection. - The market outlook points to continued investment in imaging infrastructure, radiopharmacy services and new diagnostic technologies. - Rising scan volumes and chronic disease diagnoses are keeping pressure on healthcare systems to expand access to precise imaging.

What happened: - The Business Research Company released a 2026 report on the global technetium-99m market with forecasts through 2035. - The report estimates the market will rise from $4.75 billion in 2025 to $4.99 billion in 2026. - The report forecasts the market will reach $6.01 billion by 2030. - The report links market growth to higher demand for diagnostic imaging, broader nuclear medicine adoption and healthcare expansion. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Technetium-99m, or Tc-99m, is a radioactive isotope used in nuclear medicine for diagnostic imaging. - Tc-99m emits gamma rays that are detected by gamma cameras to visualize internal organs and bodily structures. - The isotope’s roughly six-hour half-life helps reduce radiation exposure while preserving image quality. - The report cites limited radiopharmaceutical availability, cardiovascular disease prevalence, nuclear medicine infrastructure growth, government health initiatives and imaging technology improvements as historical growth drivers. - The report cites stronger demand for accurate diagnostic tools, wider hospital and imaging center networks, Tc-99m innovation, artificial intelligence in nuclear imaging and early-detection awareness as future growth drivers. - The report highlights wider SPECT imaging use, growth in cardiac and oncology diagnostics, demand for short half-life radiopharmaceuticals, expansion of centralized radiopharmacy services and tighter regulatory and safety compliance as key trends. - Diagnostic imaging demand remains a central driver because chronic diseases require timely and precise diagnosis. - NHS England reported 45.0 million imaging tests in the year to March 2023, up 2.2% from 44.0 million the prior year. - The report includes market analysis for South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report also offers market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, technology and trend analysis, and updated graphics and tables. - A free sample of the report is available here. - The full report is available here. - The Business Research Company’s website is here.

Between the lines: - The forecast suggests technetium-99m demand is being shaped less by a single procedure category and more by a broader shift toward imaging-led diagnosis across multiple specialties. - Growth in AI-enabled nuclear imaging and centralized radiopharmacy services points to a market that is becoming more operationally specialized. - Asia-Pacific’s expected lead in growth likely reflects infrastructure buildout and adoption of modern diagnostic tools rather than current market dominance.

What's next: - The market is expected to keep expanding through 2030 as hospitals and imaging centers add capacity. - Cardiac and oncology imaging demand should remain important end markets for technetium-99m. - Regulatory and safety requirements are likely to become more central as radiopharmaceutical supply chains and imaging volumes grow.

The bottom line: - Technetium-99m remains a small but essential piece of the diagnostic imaging market, with steady growth tied to aging healthcare systems, chronic disease burden and broader nuclear medicine adoption.